• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《多发性骨髓瘤的免疫疗法》简介

Introduction to "Immunotherapies for Multiple Myeloma".

作者信息

Offidani Massimo, Petrucci Maria Teresa

机构信息

Clinica di Ematologia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, via Conca, 71, 60126 Ancona, Italy.

Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, Azienda Ospedaliera Policlinico Umberto I, Università "Sapienza" di Roma, via Benevento 6, 00161 Roma, Italy.

出版信息

Pharmaceuticals (Basel). 2020 Nov 17;13(11):396. doi: 10.3390/ph13110396.

DOI:10.3390/ph13110396
PMID:33212754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7696150/
Abstract

Multiple myeloma (MM) is the second most common hematological cancer after diffuse large B-cell lymphoma, accounting for about 10% of all blood cancers [...].

摘要

多发性骨髓瘤（MM）是继弥漫性大B细胞淋巴瘤之后第二常见的血液系统癌症，约占所有血癌的10%[...]。

相似文献

1
Introduction to "Immunotherapies for Multiple Myeloma".《多发性骨髓瘤的免疫疗法》简介
Pharmaceuticals (Basel). 2020 Nov 17;13(11):396. doi: 10.3390/ph13110396.
2
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.癌症治疗中的溶瘤病毒疗法时代：应用H-1细小病毒治疗血液系统癌症和实体癌的前景
Front Oncol. 2017 May 12;7:93. doi: 10.3389/fonc.2017.00093. eCollection 2017.
3
The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period.弥漫性大 B 细胞淋巴瘤和多发性骨髓瘤幸存者在早期生存期间的焦虑、抑郁和未满足需求的过程。
J Cancer Surviv. 2017 Jun;11(3):329-338. doi: 10.1007/s11764-016-0591-y. Epub 2017 Jan 31.
4
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性，用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
5
Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.成年浆细胞骨髓瘤或弥漫性大B细胞淋巴瘤患者自体干细胞移植后骨髓造血前体细胞的定量分析及其与预后的相关性。
Leuk Lymphoma. 2018 Apr;59(4):958-966. doi: 10.1080/10428194.2017.1352094. Epub 2017 Jul 21.
6
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告：意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
7
Multiple primary cancers associated with hematological malignancies.与血液系统恶性肿瘤相关的多原发性癌症。
Jpn J Clin Oncol. 1985 Apr;15 Suppl 1:211-22.
8
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.CUDC-907（一种新型口服组蛋白去乙酰化酶（HDAC）和磷脂酰肌醇-3激酶（PI3K）双重抑制剂）在复发或难治性淋巴瘤或多发性骨髓瘤患者中的安全性、耐受性及初步活性：一项开放标签、剂量递增的1期试验。
Lancet Oncol. 2016 May;17(5):622-31. doi: 10.1016/S1470-2045(15)00584-7. Epub 2016 Mar 31.
9
In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.萘替芬对淋巴瘤和多发性骨髓瘤的体外疗效
Anticancer Res. 2015 Nov;35(11):5921-6.
10
Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.青蒿琥酯能诱导淋巴瘤细胞和骨髓瘤细胞生长停滞和凋亡，其敏感性高。
Eur J Haematol. 2013 Oct;91(4):339-46. doi: 10.1111/ejh.12176. Epub 2013 Aug 20.

引用本文的文献

1
Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.1990年至2021年全球、区域和国家多发性骨髓瘤的流行病学趋势：对《2021年全球疾病负担研究》的系统分析
Front Public Health. 2025 Jan 27;13:1527198. doi: 10.3389/fpubh.2025.1527198. eCollection 2025.
2
Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First-Line Treatment.运动训练对一线治疗后多发性骨髓瘤患者骨髓免疫微环境及微小残留病的影响
Scand J Med Sci Sports. 2025 Feb;35(2):e70020. doi: 10.1111/sms.70020.
3
CRNDE: A valuable long noncoding RNA for diagnosis and therapy of solid and hematological malignancies.CRNDE：一种用于实体瘤和血液系统恶性肿瘤诊断与治疗的重要长链非编码RNA。
Mol Ther Nucleic Acids. 2022 Mar 9;28:190-201. doi: 10.1016/j.omtn.2022.03.006. eCollection 2022 Jun 14.

本文引用的文献

1
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.AMG 701可诱导多发性骨髓瘤细胞的细胞毒性，并使食蟹猴体内的浆细胞减少。
Blood Adv. 2020 Sep 8;4(17):4180-4194. doi: 10.1182/bloodadvances.2020002565.
2
Immunotherapy of multiple myeloma.多发性骨髓瘤的免疫治疗。
J Clin Invest. 2020 Apr 1;130(4):1565-1575. doi: 10.1172/JCI129205.
3
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.多发性骨髓瘤中的单克隆抗体：当前和新兴的靶点及作用机制。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101143. doi: 10.1016/j.beha.2020.101143. Epub 2020 Jan 11.
4
Immunotherapy in Multiple Myeloma.多发性骨髓瘤的免疫治疗。
Cells. 2020 Mar 3;9(3):601. doi: 10.3390/cells9030601.
5
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.治疗性单克隆抗体及抗体产品：多发性骨髓瘤的当前实践与发展
Cancers (Basel). 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015.
6
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
7
Immunotherapy for Multiple Myeloma.多发性骨髓瘤的免疫疗法
Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009.
8
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.多发性骨髓瘤中的单克隆抗体疗法：开发新靶点面临的挑战
J Oncol. 2019 Nov 3;2019:6084012. doi: 10.1155/2019/6084012. eCollection 2019.
9
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
10
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.帕博利珠单抗联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（KEYNOTE-183）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.